Current Therapeutic Approach in Heart Failure with Preserved Ejection Fraction

Heart Failure Clinics

Volumn 10, Issue 3, 2014, Pages 525-538

  Nativi Nicolau, Jose ^a,b   Ryan, John J ^a   Fang, James C ^a,b  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Diastole; Heart failure; Therapy

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; SILDENAFIL; CARDIOTONIC AGENT; DIURETIC AGENT;

BETA ADRENERGIC RECEPTOR BLOCKING; CARDIAC RESYNCHRONIZATION THERAPY; DIASTOLIC DYSFUNCTION; ENDURANCE TRAINING; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEART VENTRICLE REMODELING; HUMAN; KIDNEY DENERVATION; PRESSORECEPTOR REFLEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM RESTRICTION; AGED; DISEASE MANAGEMENT; FEMALE; HEART FAILURE; HEART STROKE VOLUME; LIFESTYLE; MALE; MIDDLE AGED; MORTALITY; PHYSIOLOGY; PROGNOSIS; REFERENCE VALUE; RISK ASSESSMENT; RISK REDUCTION; SURVIVAL; SYNDROME; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOTONIC AGENTS; DISEASE MANAGEMENT; DIURETICS; FEMALE; HEART FAILURE; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REFERENCE VALUES; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR; STROKE VOLUME; SURVIVAL ANALYSIS; SYNDROME; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84903382534     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2014.04.007     Document Type: Review

References (91)

1. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for themanagement of heart failure: a report of theAmerican College of Cardiology Foundation/American Heart Association Task Force on PracticeGuidelines. JAm Coll Cardiol 2013, 62(16):e147-e239.
2. Zile M.R., Baicu C.F., Gaasch W.H. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. NEngl J Med 2004, 350(19):1953-1959.
3. Owan T.E., Hodge D.O., Herges R.M., et al. Secular trends in renal dysfunction and outcomes in hospitalized heart failure patients. JCard Fail 2006, 12(4):257-262.
4. Owan T.E., Hodge D.O., Herges R.M., et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. NEngl J Med 2006, 355(3):251-259.
5. Benedict C.R., Johnstone D.E., Weiner D.H., et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. JAm Coll Cardiol 1994, 23(6):1410-1420.
6. Devereux R.B., Pickering T.G., Cody R.J., et al. Relation of renin-angiotensin system activity to left ventricular hypertrophy and function in experimental and human hypertension. JClin Hypertens 1987, 3(1):87-103.
7. Hogg K., McMurray J. Neurohumoral pathways in heart failure with preserved systolic function. Prog Cardiovasc Dis 2005, 47(6):357-366.
8. Wright J.W., Mizutani S., Harding J.W. Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies. Heart Fail Rev 2008, 13(3):367-375.
9. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. NEngl J Med 1987, 316(23):1429-1435.
10. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. NEngl J Med 1991, 325(5):293-302.
11. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. NEngl J Med 1992, 327(10):685-691.
12. Cohn J.N., Johnson G., Ziesche S., et al. Acomparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. NEngl J Med 1991, 325(5):303-310.
13. Pfeffer M.A., Braunwald E., Moye L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. NEngl J Med 1992, 327(10):669-677.
14. Cohn J.N., Tognoni G., Valsartan Heart I. Failure trial, a randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. NEngl J Med 2001, 345(23):1667-1675.
15. Granger C.B., McMurray J.J., Yusuf S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003, 362(9386):772-776.
16. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359(9311):995-1003.
17. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. NEngl J Med 2000, 342(3):145-153.
18. Fox K.M., EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003, 362(9386):782-788.
19. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362(9386):777-781.
20. Cleland J.G., Tendera M., Adamus J., et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006, 27(19):2338-2345.
21. Massie B.M., Carson P.E., McMurray J.J., et al. Irbesartan in patients with heart failure and preserved ejection fraction. NEngl J Med 2008, 359(23):2456-2467.
22. Lund L.H., Benson L., Dahlstrom U., et al. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA 2012, 308(20):2108-2117.
23. Mujib M., Patel K., Fonarow G.C., et al. Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction. Am J Med 2013, 126(5):401-410.
24. Kobayashi M., Machida N., Mitsuishi M., et al. Beta-blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure. Am J Hypertens 2004, 17(12 Pt 1):1112-1119.
25. Nishio M., Sakata Y., Mano T., et al. Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats. Eur J Heart Fail 2008, 10(5):446-453.
26. Dobre D., van Veldhuisen D.J., DeJongste M.J., et al. Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival. Eur J Heart Fail 2007, 9(3):280-286.
27. Hernandez A.F., Hammill B.G., O'Connor C.M., et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. JAm Coll Cardiol 2009, 53(2):184-192.
28. Conraads V.M., Metra M., Kamp O., et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail 2012, 14(2):219-225.
29. Flather M.D., Shibata M.C., Coats A.J., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005, 26(3):215-225.
30. van Veldhuisen D.J., Cohen-Solal A., Bohm M., et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). JAm Coll Cardiol 2009, 53(23):2150-2158.
31. Yamamoto K., Origasa H., Hori M., et al. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 2013, 15(1):110-118.
32. Brilla C.G., Weber K.T. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. JLab Clin Med 1992, 120(6):893-901.
33. Tomaschitz A., Pilz S., Ritz E., et al. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J 2010, 31(10):1237-1247.
34. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. NEngl J Med 1999, 341(10):709-717.
35. Zannad F., McMurray J.J., Krum H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. NEngl J Med 2011, 364(1):11-21.
36. Edelmann F., Tomaschitz A., Wachter R., et al. Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction. Eur Heart J 2012, 33(2):203-212.
37. Edelmann F., Wachter R., Schmidt A.G., et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013, 309(8):781-791.
38. Stiles Steve. Aldo-antagonist falls short but impresses in preserved-EF heart failure: TOPCAT. 2013. Available at: http://www.medscape.com/viewarticle/814622.
39. Paulus W.J., Tschope C. Anovel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. JAm Coll Cardiol 2013, 62(4):263-271.
40. Greene S.J., Gheorghiade M., Borlaug B.A., et al. The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. JAm Heart Assoc 2013, 2(6):e000536.
41. Nagendran J., Archer S.L., Soliman D., et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 2007, 116(3):238-248.
42. Shan X., Quaile M.P., Monk J.K., et al. Differential expression of PDE5 infailing and nonfailing human myocardium. Circ Heart Fail 2012, 5(1):79-86.
43. Takimoto E., Champion H.C., Li M., et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005, 11(2):214-222.
44. Nagayama T., Hsu S., Zhang M., et al. Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. JAm Coll Cardiol 2009, 53(2):207-215.
45. Al-Hesayen A., Floras J.S., Parker J.D. The effects of intravenous sildenafil on hemodynamics and cardiac sympathetic activity in chronic human heart failure. Eur J Heart Fail 2006, 8(8):864-868.
46. Galie N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. NEngl J Med 2005, 353(20):2148-2157.
47. Rubin L.J., Badesch D.B., Fleming T.R., et al. Long-term treatment with sildenafilcitrate in pulmonary arterial hypertension: the SUPER-2 study. Chest 2011, 140(5):1274-1283.
48. Guazzi M., Vicenzi M., Arena R., et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011, 124(2):164-174.
49. Schwartzenberg S., Redfield M.M., From A.M., et al. Effects of vasodilation inheart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. JAm Coll Cardiol 2012, 59(5):442-451.
50. Drazner M.H., Prasad A., Ayers C., et al. The relationship of right- and left-sided filling pressures in patients with heart failure and a preserved ejection fraction. Circ Heart Fail 2010, 3(2):202-206.
51. Redfield M.M., Chen H.H., Borlaug B.A., et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: arandomized clinical trial. JAMA 2013, 309(12):1268-1277.
52. Gardner D.G., Chen S., Glenn D.J., et al. Molecular biology of the natriuretic peptide system: implications for physiology and hypertension. Hypertension 2007, 49(3):419-426.
53. Potter L.R., Abbey-Hosch S., Dickey D.M. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 2006, 27(1):47-72.
54. Gu J., Noe A., Chandra P., et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). JClin Pharmacol 2010, 50(4):401-414.
55. McClean D.R., Ikram H., Garlick A.H., et al. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. JAm Coll Cardiol 2000, 36(2):479-486.
56. Eisenstein E.L., Nelson C.L., Simon T.A., et al. Vasopeptidase inhibitor reduces in-hospital costs for patients with congestive heart failure: results from the IMPRESS trial. Inhibition of Metallo Protease by BMS-186716 in a Randomized Exercise and Symptoms Study in Subjects With Heart Failure. Am Heart J 2002, 143(6):1112-1117.
57. Gronholm T., Cheng Z.J., Palojoki E., et al. Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats. Eur J Pharmacol 2005, 519(3):267-276.
58. Solomon S.D., Zile M., Pieske B., et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failurewith preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012, 380(9851):1387-1395.
59. Lenzen M.J., Scholte Reimer W.J., Boersma E., et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J 2004, 25(14):1214-1220.
60. Fukuta H., Sane D.C., Brucks S., et al. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005, 112(3):357-363.
61. Shah R., Wang Y., Foody J.M. Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients
62. Florkowski C.M., Molyneux S.L., George P.M. Rosuvastatin in older patients with systolic heart failure. NEngl J Med 2008, 358(12):1301. [author reply: 1301].
63. Liu G., Xin-Xin Zheng, Yan-Lu Xu, et al. Meta-analysis of the effect of statins on mortality in patients with preserved ejection fraction. Am J Cardiol 2014, 113(7):1198-1204.
64. Klotz S., Hay I., Zhang G., et al. Development of heart failure in chronic hypertensive Dahl rats: focus on heart failure with preserved ejection fraction. Hypertension 2006, 47(5):901-911.
65. Matsui H., Ando K., Kawarazaki H., et al. Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder. Hypertension 2008, 52(2):287-294.
66. Sadanaga T., Ando K., Hirota S., et al. B-type natriuretic peptide levels are decreased by reducing dietary salt intake in patients with compensated heart failure with preserved ejection fraction. Intern Med J 2013, 43(6):663-667.
67. Hummel S.L., Seymour E.M., Brook R.D., et al. Low-sodium dietary approaches to stop hypertension diet reduces blood pressure, arterial stiffness, and oxidative stress in hypertensive heart failure with preserved ejection fraction. Hypertension 2012, 60(5):1200-1206.
68. Hummel S.L., Seymour E.M., Brook R.D., et al. Low-sodium DASH diet improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with preserved ejection fraction. Circ Heart Fail 2013, 6(6):1165-1171.
69. Kitzman D.W., Brubaker P.H., Herrington D.M., et al. Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. JAm Coll Cardiol 2013, 62(7):584-592.
70. Edelmann F., Gelbrich G., Dungen H.D., et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol 2011, 58:1780-1791.
71. Borlaug B.A., Melenovsky V., Russell S.D., et al. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 2006, 114(20):2138-2147.
72. Brubaker P.H., Joo K.C., Stewart K.P., et al. Chronotropic incompetence and its contribution to exercise intolerance in older heart failure patients. JCardiopulm Rehabil 2006, 26(2):86-89.
73. Kass D.A., Kitzman D.W., Alvarez G.E. The restoration of chronotropic competence in heart failure patients with normal ejection fraction (RESET) study: rationale and design. JCard Fail 2010, 16(1):17-24.
74. Eicher J.C., Laurent G., Mathe A., et al. Atrial dyssynchrony syndrome: anoverlooked phenomenon and a potential cause of 'diastolic' heart failure. Eur J Heart Fail 2012, 14(3):248-258.
75. Phan T.T., Abozguia K., Shivu G.N., et al. Myocardial contractile inefficiency and dyssynchrony in heart failure with preserved ejection fraction and narrow QRS complex. JAm Soc Echocardiogr 2010, 23(2):201-206.
76. Morris D.A., Vaz Perez A., Blaschke F., et al. Myocardial systolic and diastolicconsequences of left ventricular mechanical dyssynchrony in heart failure with normal left ventricular ejection fraction. Eur Heart J Cardiovasc Imaging 2012, 13(7):556-567.
77. De Sutter J., Van de Veire N.R., Muyldermans L., et al. Prevalence of mechanical dyssynchrony in patients with heart failure and preserved left ventricular function (a report from the Belgian Multicenter Registry on dyssynchrony). Am J Cardiol 2005, 96(11):1543-1548.
78. Yu C.M., Zhang Q., Yip G.W., et al. Diastolic and systolic asynchrony in patients with diastolic heart failure: a common but ignored condition. JAm Coll Cardiol 2007, 49(1):97-105.
79. Santos A.B., Kraigher-Krainer E., Bello N., et al. Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. Eur Heart J 2014, 35(1):42-47.
80. Bisognano J.D., Bakris G., Nadim M.K., et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. JAm Coll Cardiol 2011, 58(7):765-773.
81. James P.A., Oparil S., Carter B.L., et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014, 311:507-520.
82. Zakeri R., Borlaug B.A., McNulty S.E., et al. Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. Circ Heart Fail 2014, 7:123-130.
83. Machino-Ohtsuka T., Seo Y., Ishizu T., et al. Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction. JAm Coll Cardiol 2013, 62(20):1857-1865.
84. Fuster V., Ryden L.E., Cannom D.S., et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011, 57:e101-e198.
85. Hwang S.J., Melenovsky V., Borlaug B.A. Implications of Coronary Artery Disease in Heart Failure with preserved Ejection Fraction. J Am Coll Cardiol 2014.
86. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012, 14:803-869.
87. Ahmed A., Rich M.W., Fleg J.L., et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 2006, 114:397-403.
88. Setaro J.F., Zaret B.L., Schulman D.S., et al. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 1990, 66:981-986.
89. Hung M.J., Cherng W.J., Kuo L.T., et al. Effect of verapamil in elderly patients with left ventricular diastolic dysfunction as a cause of congestive heart failure. Int J Clin Pract 2002, 56:57-62.
90. Maier L.S., Layug B., Karwatowska-Prokopczuk E., et al. RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study. JACC Heart Fail 2013, 1:115-122.
91. Kosmala W., Holland D.J., Rojek A., et al. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol 2013, 62:1330-1338.